Metagenomi, Inc. (NASDAQ:MGX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.00.

Several analysts have issued reports on MGX shares. Wells Fargo & Company dropped their price target on Metagenomi from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen raised Metagenomi from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings downgraded Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th.

Metagenomi Price Performance

MGX opened at $1.33 on Wednesday. The business’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.54. Metagenomi has a 1 year low of $1.24 and a 1 year high of $3.95. The company has a market capitalization of $50.07 million, a price-to-earnings ratio of -0.58 and a beta of 0.64.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Metagenomi had a negative net margin of 384.61% and a negative return on equity of 51.23%. The firm had revenue of $1.25 million during the quarter, compared to analyst estimates of $5.90 million. Sell-side analysts anticipate that Metagenomi will post -2.13 earnings per share for the current fiscal year.

Institutional Trading of Metagenomi

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Metagenomi by 4,155.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 62,559 shares of the company’s stock valued at $148,000 after purchasing an additional 61,089 shares during the period. Man Group plc acquired a new stake in shares of Metagenomi in the 3rd quarter valued at about $125,000. AQR Capital Management LLC acquired a new stake in shares of Metagenomi in the 1st quarter valued at about $119,000. XTX Topco Ltd increased its position in shares of Metagenomi by 353.4% in the fourth quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock valued at $112,000 after acquiring an additional 53,778 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Metagenomi by 482.9% in the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock valued at $76,000 after acquiring an additional 17,491 shares during the last quarter.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.